|  |
| --- |
| **Supplementary Table 2.** Recruitment details and medium compositions of human endometrial organoid studies |
| **Author, Year** | **Subjects** | **Medium name** | **EGF Pathway** | **WNT Pathway** | **BMP** **inhibition** | **FGF Pathway** | **HGF Pathway** | **Small molecules** | **p38 MAPK-Inhibition** | **Hormones** | **Other relevant ingredients** |
| **EGF (ng/mL)** | **Wnt3a¶** | **R-SPO-1¶** | **Noggin¶**  | **FGF-2/-7/****FGF-10****(ng/mL)** | **HGF****(ng/mL)** | **A83-01** **or** **SB 43152****(nM)** | **NAM (mM)** | **Y-27632** **(µM)** | **SB 202190** **(µM)** | **E2****(nM)** | **Other hormones or small molecules** | **Fetal calf serum****(%)** |
| **Endometrium: atrophic, proliferative, secretory - Endometrial hyperplasia - Endometriosis: eutopic, ectopic - Endometrioid endometrial cancer (EEC) - other EC** |
| Turco et al., 2017;Fitzgerald et al. 2019;Luddi et al., 2020 | Atrophy, N=1;Proliferative, N=3;Secretory, N=11;EEC, N=3 | ExM | 50 |  | 500 | 100 | FGF-10:100 | 50 | A83-01:500 | 10 | 10 |  | 10**§** | NAC: 1.25 mM P4**§**: 1 µM, Prolactin**§**: 20 ng/mL,hCG**§**: 1 µg/mLhPL**§**: 20 ng/mLcAMP**§**: 1 µM; | 10† |
| Boretto et al., 2017; Hennes et al., 2019 | All phases, N=N/A | Human organoid culture medium | 50 | 200 | 200 | 100 | FGF-10:50 |  | A83-01:500 | 1 | 9\* | 10 | 2 | Insulin: 1 %;NAC: 1.25 mMP4**§**: 50 ng/mL | 10† |
| Dasari et al., 2017 | EEC, N=N/A |  | 20 |  |  |  | FGF-2:10 |  |  |  |  |  |  | Insulin: 50 µg/mLBSA: 0.4% |  |
| Girda et al., 2017 | EEC, N=15 |  |  |  |  |  |  |  | A83-01:500 | 10 | 10 | 3 | 1 |  |  |
| Pauli et al., 2017 | EEC, N=1Other EC, N=1 | CHM | 50 |  | 25% | 50% | FGF-2:1FGF-10:20 |  | A83-01:500 | 10 | 10 | 10 |  | NAC: 1.25 mMPGE2: 1 µM | 10† |
| Boretto et al., 2019*and*Esfandiari et al, 2020 | Healthy, N=15/9;Endometriosis, N=21/16;Hyperplasia, N=11; | Standard | 50 |  | 10% | 100 | FGF-2: 2FGF-10:10 |  | A83-01:500 | 2 | 10\* | 10 | 1 | Insulin: 1%;NAC: 1.25 mM | 10† |
| EEC, N=11;Other EC, N=2 | Optimized | 50 |  | 5% | 100 |  | 20 | A83-01:250 | 5 | 10\* | 0.1 | 10 | IGF-1: 40 ng/mLNAC: 1.25 mMChemically defined lipid concentrate: 1% | 10† |
| Maru et al., 2019a | EEC, N=5Other EC, N=1 |  | 50 |  | 250 | 100 |  |  |  |  | 10 |  |  | Jagged-1: 1 μM | 10‡ |
| Cochrane et al., 2020 | Secretory,N=3 | ExM | 10 | 25% | 25% | 100 | FGF-10:100 |  | SB 431542:500 | 1 | 9 |  |  |  | 5 |

**¶ Provided in ng/mL or % Conditioned medium (CM)
† during sample dissection/digestion
‡ during sample seeding
§ for differentiation**\* **only for formation or dissociation at passaging**